This website is intended for healthcare professionals only.
ADDRESSING THE UNMET NEEDS IN 3L mGC: A CLINICAL PERSPECTIVE
Prof Sylvie Lorenzen
MD, PhD
Head of the Phase I Unit, University Hospital rechts der Isar, Technical University of Munich, Germany
Dr Elizabeth Smyth
MD
Oncology Department Addenbrooke's Hospital, Cambridge, United Kingdom
This webinar presents the differences and similarities between metastatic gastric cancer (mGC) and metastatic colorectal cancer (mCRC) in terms of patients profiles, therapeutic objectives, and standard of care. It hightlights the need to increase the number of patients reaching 3L+ , and presents clinical results of approved 3L+ treatments for each condition. In addition, it emphasizes the importance of tailoring according to treatment goals. Two interactive clinical cases discuss 3L treatment choices and continuum of care in mGC and mCRC.
Key points covered
This webinar highlights the challenges faced in treating mGC patients and the importance of therapeutic sequencing.
mGC tumour heterogeneity is a major challenge for developing effective targeted drugs
Distinct patient subgroups may benefit from immune checkpoint therapy
FTD/TPI is the recommended option in 3L
Sequential treatment strategy is a goal
Webinar Replay
Featured Speakers
Prof Sylvie Lorenzen
Prof Lorenzen’s research interests include clinical research in medical oncology, response evaluation in solid tumor therapy, and multimodality treatment of gastrointestinal cancer. She is the head of the gastro-esophageal working group of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Dr Elizabeth Smyth
Dr Smyth’s research is on clinical trials and translational research in gastroesophageal cancer. She has worked on trial design, management of national and international trials, and is the gastric taskforce lead of the EORTC GI Trials Group and VC of the ESMO Oncology PRO Working Group.
